Novo Nordisk’s leading drug Ozempic (semaglutide) is forecast to demonstrate a sales growth of 23% in 2023. Ozempic’s forecast 2023 sales of $12.5bn consolidate its position as the dominant market leader, with projected sales in 2023 54% greater than closest competitor Trulicity (dulaglutide) by Eli Lilly, which anticipates sales of $8bn.

Originally granted approval in its largest market, the US, in 2017, Ozempic has subsequently obtained approval for three distinct dosages, 0.5mg, 1.0mg, and 2.0mg, for the treatment of type 2 diabetes. FDA approval follows the successful outcomes of the Sustain Forte trial (NCT03989232), the results of which displayed a superior reduction in HbA1c levels with once-weekly semaglutide 2.0mg, in comparison to once-weekly semaglutide 1.0mg, among individuals suffering from type 2 diabetes. Ozempic is a recombinant peptide indicated to reduce the risk of major cardiovascular events such as strokes, heart attacks, or mortality among adults with type 2 diabetes and established heart disease. The drug is based on protein acylation technology and works to reduce blood sugar by enhancing glucose-dependent insulin secretion from the pancreas, as well as reducing glucagonemia and body weight.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029. This represents a significant 83% increase in sales between 2022–2029, demonstrating a compound annual growth rate (CAGR) of 9%.

Novo Nordisk and Sanofi’s announcement in March 2023 to join Eli Lilly in major price reductions for pre-filled insulin pens and vials may suggest a potential shift in the dynamic insulin market. Ozempic’s significance in the evolving pharmaceutical landscape is evident through its increasing popularity as a next-generation medication for diabetes, with notable attention towards its off-label application as a weight-loss agent. The substantial weight loss that patients achieve with Ozempic and other GLP1-targeting drugs makes insulin requirements lower for patients with type 2 diabetes, incentivising both patients and healthcare practitioners to consider this medication. This change in insulin access within the US market will therefore play a crucial role in Ozempic’s commercial success and may contribute to the observed revenue growth.

The significant sales growth of Ozempic reinforces its continued dominance in the type 2 diabetes market. As attitudes towards insulin access evolve, Ozempic is well-positioned to provide support to a greater number of patients suffering from type 2 diabetes, facilitating improvements in their quality of life.